- Home
- GDTC vs BOLD Comparison
GDTC vs BOLD Comparison
Compare GDTC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- BOLD
- Stock Information
- Founded
- GDTC 2018
- BOLD 2018
- Country
- GDTC Singapore
- BOLD United States
- Employees
- GDTC N/A
- BOLD N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- GDTC Health Care
- BOLD
- Exchange
- GDTC Nasdaq
- BOLD Nasdaq
- Market Cap
- GDTC 28.0M
- BOLD 24.4M
- IPO Year
- GDTC 2023
- BOLD 2024
- Fundamental
- Price
- GDTC $2.02
- BOLD $1.14
- Analyst Decision
- GDTC Buy
- BOLD Buy
- Analyst Count
- GDTC 1
- BOLD 3
- Target Price
- GDTC $5.00
- BOLD $4.00
- AVG Volume (30 Days)
- GDTC 7.9K
- BOLD 278.2K
- Earning Date
- GDTC 01-01-0001
- BOLD 08-11-2025
- Dividend Yield
- GDTC N/A
- BOLD N/A
- EPS Growth
- GDTC N/A
- BOLD N/A
- EPS
- GDTC N/A
- BOLD N/A
- Revenue
- GDTC $368,838.00
- BOLD N/A
- Revenue This Year
- GDTC $5.37
- BOLD N/A
- Revenue Next Year
- GDTC N/A
- BOLD N/A
- P/E Ratio
- GDTC N/A
- BOLD N/A
- Revenue Growth
- GDTC N/A
- BOLD N/A
- 52 Week Low
- GDTC $1.20
- BOLD $1.00
- 52 Week High
- GDTC $4.05
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- GDTC 39.37
- BOLD N/A
- Support Level
- GDTC $2.01
- BOLD N/A
- Resistance Level
- GDTC $2.22
- BOLD N/A
- Average True Range (ATR)
- GDTC 0.10
- BOLD 0.00
- MACD
- GDTC -0.02
- BOLD 0.00
- Stochastic Oscillator
- GDTC 2.94
- BOLD 0.00
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.